phone

Warts - Pipeline Review, H2 2017

  • Published Date: 18 Jul 2017
  • Number of Pages: 86
  • Category: Pharmaceuticals
  • Country: Global
Warts - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Warts - Pipeline Review, H2 2017, provides an overview of the Warts (Infectious Disease) pipeline landscape.

Warts are skin growth that is caused by virus called human papillomavirus (HPV). HPV infects the top layer of skin, usually entering the body in an area of broken skin. The virus causes the top layer of skin to grow rapidly, forming a wart. Symptoms include pain and rough skin. Predisposing factors include age and people with weakened immune systems, such as those with HIV/AIDS or people who had organ transplants.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Warts - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Warts (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Warts (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Warts and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 16, 1, 6 and 3 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Warts (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Warts (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Warts (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Warts (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Warts (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Warts (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Warts (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Warts (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Publisher Name : Global Markets Direct

Introduction 5
Global Markets Direct Report Coverage 5
Warts - Overview 6
Warts - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 11
Products under Development by Companies 12
Products under Development by Universities/Institutes 14
Warts - Therapeutics Assessment 15
Assessment by Target 15
Assessment by Mechanism of Action 17
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Warts - Companies Involved in Therapeutics Development 23
Aclaris Therapeutics Inc 23
Agilvax Inc 23
Aviragen Therapeutics Inc 24
BioMAS Ltd 24
Cutanea Life Sciences Inc 25
Cytovation AS 25
Foamix Pharmaceuticals Ltd 26
G&E Herbal Biotechnology Co Ltd 26
Laboratories Ojer Pharma SL 27
LEO Pharma A/S 27
Nielsen Biosciences Inc 28
Novan Inc 28
Novartis AG 29
Promius Pharma LLC 29
RXi Pharmaceuticals Corp 30
Tamir Biotechnology Inc 30
Zydus Cadila Healthcare Ltd 31
Warts - Drug Profiles 32
(digoxin + furosemide) - Drug Profile 32
854-A - Drug Profile 34
Albicin - Drug Profile 35
AS-101 - Drug Profile 36
AX-03 - Drug Profile 38
BTA-074 - Drug Profile 40
CyPep-1 - Drug Profile 42
DFD-05 - Drug Profile 43
FIT-039 - Drug Profile 44
furosemide - Drug Profile 45
human papillomavirus [serotypes 6, 11] (bivalent) vaccine - Drug Profile 46
human papillomavirus vaccine - Drug Profile 47
human papillomavirus vaccine - Drug Profile 48
hydrogen peroxide - Drug Profile 49
imiquimod - Drug Profile 52
imiquimod SR - Drug Profile 53
ingenol mebutate - Drug Profile 54
interferon alfa-2b - Drug Profile 56
LFX-453 - Drug Profile 57
omiganan pentahydrochloride - Drug Profile 58
povidone iodine - Drug Profile 60
PP-210 - Drug Profile 61
ranpirnase - Drug Profile 62
RKP-00156 - Drug Profile 65
Samcyprone - Drug Profile 66
SB-206 - Drug Profile 68
SRT-100 - Drug Profile 70
VP-100 - Drug Profile 72
Warts - Dormant Projects 73
Warts - Discontinued Products 74
Warts - Product Development Milestones 75
Featured News & Press Releases 75
Appendix 83
Methodology 83
Coverage 83
Secondary Research 83
Primary Research 83
Expert Panel Validation 83
Contact Us 83
Disclaimer 84

List Of Tables


Number of Products under Development for Warts, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Warts - Pipeline by Aclaris Therapeutics Inc, H2 2017
Warts - Pipeline by Agilvax Inc, H2 2017
Warts - Pipeline by Aviragen Therapeutics Inc, H2 2017
Warts - Pipeline by BioMAS Ltd, H2 2017
Warts - Pipeline by Cutanea Life Sciences Inc, H2 2017
Warts - Pipeline by Cytovation AS, H2 2017
Warts - Pipeline by Foamix Pharmaceuticals Ltd, H2 2017
Warts - Pipeline by G&E Herbal Biotechnology Co Ltd, H2 2017
Warts - Pipeline by Laboratories Ojer Pharma SL, H2 2017
Warts - Pipeline by LEO Pharma A/S, H2 2017
Warts - Pipeline by Nielsen Biosciences Inc, H2 2017
Warts - Pipeline by Novan Inc, H2 2017
Warts - Pipeline by Novartis AG, H2 2017
Warts - Pipeline by Promius Pharma LLC, H2 2017
Warts - Pipeline by RXi Pharmaceuticals Corp, H2 2017
Warts - Pipeline by Tamir Biotechnology Inc, H2 2017
Warts - Pipeline by Zydus Cadila Healthcare Ltd, H2 2017
Warts - Dormant Projects, H2 2017
Warts - Discontinued Products, H2 2017

List Of Figures


Number of Products under Development for Warts, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Warts - Pipeline Review, H2 2017 Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Warts - Pipeline Review, H2 2017, provides an overview of the Warts (Infectious Disease) pipeline

View Report

Genital Warts (Condylomata Acuminata) Global Clinical Trials Review, H1, 2015 market research report at USD 2500 and market update available at JSB Market Research.

View Report

Wartsila Corporation (WRT1V) - Alternative Energy - Deals and Alliances Profile market research report at USD 250 and market update available at JSB Market Research.

View Report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports